drugset / Trial / NCT03944902
CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this protocol is to investigate the efficacy of the combination of CB-839 with Niraparib in platinum resistant BRCA wild-type ovarian cancer patients. The primary and secondary objectives are to determine the maximum tolerated dose of CB-839 in combination with Niraparib and to determine the response rate and percentage of participants who remain progression free at 6 months.
Timeline
- Start
- 2021-09-01
- Primary completion
- 2022-01-05
- Completion
- 2022-01-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CB-839 | Unknown | 600 mg | — |
| Subject | CB-839 | Unknown | 800 mg | — |
| Subject | Niraparib | Small molecule | — | — |